{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:13:33Z","timestamp":1789470813698,"version":"build-2803163510"},"reference-count":48,"publisher":"Scientific Scholar","content-domain":{"domain":["cytojournal.com"],"crossmark-restriction":true},"short-container-title":["Cytojournal"],"abstract":"\n Objective:<\/jats:title>\n Colorectal cancer (CRC) is a malignancy known for its aggressive behavior and notable mortality burden. Indoleamine 2,3-dioxygenase 1 (IDO1), an immune checkpoint molecule, is markedly upregulated in CRC, and it has been implicated in the regulation of key components of the ferroptosis pathway. This study aimed to elucidate the regulatory interaction between IDO1 and ferroptosis and assess the potential therapeutic effect of combined IDO1 inhibition with ferroptosis inducers Erastin and RSL3 in CRC.<\/jats:p>\n <\/jats:sec>\n \n Material and Methods:<\/jats:title>\n \n Three CRC cell lines (CT26, MC38, and HT-29) and one normal colon epithelial cell line (NCM460) were treated with ferroptosis inducers to evaluate the changes in IDO1 expression through reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blotting. MC38 cells with stable IDO1 knockdown were generated through lentiviral transduction. The expressions of ferroptosis-related genes following IDO1 silencing were assessed through RT-qPCR and Western blot. The antitumor efficacy of combined IDO1 knockdown and Erastin\/RSL3 treatment was evaluated through cell counting kit-8, Transwell migration, and wound-healing assays. Enzyme-linked immunosorbent assay was employed to quantify intracellular levels of glutathione (GSH) and malondialdehyde (MDA). Reactive oxygen species (ROS) levels were measured via flow cytometry, and ferrous ion (Fe\n 2+<\/jats:sup>\n )and nicotinamide adenine dinucleotide phosphate (NADPH) concentrations were determined through colorimetric analysis.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Treatment with Erastin and RSL3 upregulated IDO1 expression in CRC cells. Silencing of IDO1 in MC38 cells resulted in increased expressions of cyclooxygenase-2, acyl-CoA synthetase long chain family member 4, and NADPH oxidase 1, alongside decreased expression of GSH peroxidase 4, solute carrier family 7 member 11, ferritin heavy chain 1, and nuclear factor E2-related factor 2. The combination of IDO1 knockdown with Erastin\/RSL3 treatment significantly reduced the proliferation, invasion, and migration of MC38 cells (\n P<\/jats:italic>\n < 0.001). This combined treatment also elevated intracellular MDA, ROS, and Fe\n 2+<\/jats:sup>\n levels while lowering GSH and NADPH levels.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Combination therapy with IDO1 inhibitor and ferroptosis inducer may be an effective way to improve treatment efficacy in CRC.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/cytojournal_262_2024","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:25:27Z","timestamp":1780143927000},"page":"32","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combine immune checkpoint indoleamine 2,3-dioxygenase 1 knockdown with ferroptosis inducer Erastin\/RSL3 accelerates colorectal cancer cell ferroptosis"],"prefix":"10.25259","volume":"23","author":[{"given":"Fei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Taizhou Central Hospital, Taizhou, Zhejiang, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taixi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingpei","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Taizhou Traditional Chinese Medicine Hospital, Taizhou, Zhejiang, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Taizhou Central Hospital, Taizhou, Zhejiang, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Taizhou Central Hospital, Taizhou, Zhejiang, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Taizhou Traditional Chinese Medicine Hospital, Taizhou, Zhejiang, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"10.25259\/Cytojournal_262_2024\/ref-1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.25259\/Cytojournal_262_2024\/ref-2","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.25259\/Cytojournal_262_2024\/ref-3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2020.04.016","article-title":"Metabolic alterations in the tumor microenvironment and their role in oncogenesis","volume":"484","author":"Eisenberg","year":"2020","journal-title":"Cancer Lett"},{"key":"10.25259\/Cytojournal_262_2024\/ref-4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/cells10020304","article-title":"Mapping the metabolic networks of tumor cells and cancer-associated fibroblasts","volume":"10","author":"Karta","year":"2021","journal-title":"Cells"},{"key":"10.25259\/Cytojournal_262_2024\/ref-5","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.cmet.2023.06.004","article-title":"Tryptophan metabolism in health and disease","volume":"35","author":"Xue","year":"2023","journal-title":"Cell Metab"},{"key":"10.25259\/Cytojournal_262_2024\/ref-6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/08830185.2021.1954638","article-title":"Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system","volume":"41","author":"Ala","year":"2022","journal-title":"Int Rev Immunol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-7","doi-asserted-by":"publisher","first-page":"BSR20221682","DOI":"10.1042\/BSR20221682","article-title":"Tryptophan metabolism and disposition in cancer biology and immunotherapy","volume":"42","author":"Badawy","year":"2022","journal-title":"Biosci Rep"},{"key":"10.25259\/Cytojournal_262_2024\/ref-8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: A Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.intimp.2017.03.024","article-title":"IDO1: An important immunotherapy target in cancer treatment","volume":"47","author":"Li","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.trsl.2015.07.003","article-title":"Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer","volume":"167","author":"Santhanam","year":"2016","journal-title":"Transl Res"},{"key":"10.25259\/Cytojournal_262_2024\/ref-11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2020.12.001","article-title":"Tryptophan and indole metabolism in immune regulation","volume":"70","author":"Fiore","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/bjc.2011.513","article-title":"Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer","volume":"106","author":"Ferdinande","year":"2012","journal-title":"Br J Cancer"},{"key":"10.25259\/Cytojournal_262_2024\/ref-13","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3748\/wjg.v24.i20.2181","article-title":"Indoleamine-2,3-dioxygenase 1\/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer","volume":"24","author":"Ma","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jamaoncol.2020.5572","article-title":"Effect of taxane chemotherapy with or without indoximod in metastatic breast cancer: A randomized clinical trial","volume":"7","author":"Mariotti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/jcph.855","article-title":"Population pharmacokinetic and pharmacodynamic modeling of epacadostat in patients with advanced solid malignancies","volume":"57","author":"Shi","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.25259\/Cytojournal_262_2024\/ref-17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: Past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.25259\/Cytojournal_262_2024\/ref-18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: A novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer"},{"key":"10.25259\/Cytojournal_262_2024\/ref-19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","article-title":"Ferroptosis in cancer and cancer immunotherapy","volume":"42","author":"Zhao","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.25259\/Cytojournal_262_2024\/ref-20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.21037\/atm-21-6942","article-title":"The critical role and molecular mechanisms of ferroptosis in antioxidant systems: A narrative review","volume":"10","author":"Liu","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.25259\/Cytojournal_262_2024\/ref-21","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","article-title":"The role of erastin in ferroptosis and its prospects in cancer therapy","volume":"13","author":"Zhao","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.25259\/Cytojournal_262_2024\/ref-22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.25259\/Cytojournal_123_2024","article-title":"PR\/SET domain 1 targeting glutathione peroxidase 4 regulates chronic hepatitis B liver fibrosis through ferroptosis","volume":"21","author":"Wu","year":"2024","journal-title":"Cytojournal"},{"key":"10.25259\/Cytojournal_262_2024\/ref-23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1902719","article-title":"The gut microbiota metabolite capsiate promotes Gpx4 expression by activating TRPV1 to inhibit intestinal ischemia reperfusion-induced ferroptosis","volume":"13","author":"Deng","year":"2021","journal-title":"Gut Microbes"},{"key":"10.25259\/Cytojournal_262_2024\/ref-24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.molcel.2022.02.007","article-title":"Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling","volume":"82","author":"Fiore","year":"2022","journal-title":"Mol Cell"},{"key":"10.25259\/Cytojournal_262_2024\/ref-25","doi-asserted-by":"publisher","first-page":"e64806","DOI":"10.7554\/eLife.64806","article-title":"Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism","volume":"10","author":"Zeitler","year":"2021","journal-title":"Elife"},{"key":"10.25259\/Cytojournal_262_2024\/ref-26","doi-asserted-by":"publisher","first-page":"E7776","DOI":"10.1073\/pnas.1805523115","article-title":"Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response","volume":"115","author":"Nakamura","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.25259\/Cytojournal_262_2024\/ref-27","doi-asserted-by":"publisher","first-page":"111295","DOI":"10.1016\/j.biopha.2021.111295","article-title":"The emerging roles of IDO2 in cancer and its potential as a therapeutic target","volume":"137","author":"Li","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.25259\/Cytojournal_262_2024\/ref-28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12032-017-0933-2","article-title":"Targeting TDO in cancer immunotherapy","volume":"34","author":"Yu","year":"2017","journal-title":"Med Oncol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-29","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 is a metabolic immune checkpoint that activates the ahr and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"key":"10.25259\/Cytojournal_262_2024\/ref-30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.25259\/Cytojournal_262_2024\/ref-31","doi-asserted-by":"publisher","first-page":"e2102315","DOI":"10.1002\/adhm.202102315","article-title":"Anti-PD-L1 dnazyme loaded photothermal MN2+\/Fe3+ hybrid metal-phenolic networks for cyclically amplified tumor ferroptosisimmunotherapy","volume":"11","author":"Liu","year":"2022","journal-title":"Adv Healthc Mater"},{"key":"10.25259\/Cytojournal_262_2024\/ref-32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00018-022-04365-4","article-title":"Inhibition of ALG3 stimulates cancer cell immunogenic ferroptosis to potentiate immunotherapy","volume":"79","author":"Liu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.25259\/Cytojournal_262_2024\/ref-33","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res"},{"key":"10.25259\/Cytojournal_262_2024\/ref-34","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1038\/s41467-022-33285-x","article-title":"USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"10.25259\/Cytojournal_262_2024\/ref-35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/SLA.0000000000002754","article-title":"IDO1 expression is associated with immune tolerance and poor prognosis in patients with surgically resected esophageal cancer","volume":"269","author":"Kiyozumi","year":"2019","journal-title":"Ann Surg"},{"key":"10.25259\/Cytojournal_262_2024\/ref-36","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.drup.2023.100947","article-title":"PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity","volume":"68","author":"Du","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.25259\/Cytojournal_262_2024\/ref-37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/PAI.0000000000000761","article-title":"Expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophanyl-tRNA synthetase (WARS) in gastric cancer molecular subtypes","volume":"28","author":"Lu","year":"2020","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-38","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1021\/acs.jmedchem.2c01954","article-title":"Dual nicotinamide phosphoribosyltransferase (NAMPT) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors for the treatment of drug-resistant nonsmall-cell lung cancer","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.25259\/Cytojournal_262_2024\/ref-39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-021-01847-4","article-title":"What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past","volume":"40","author":"Yao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.25259\/Cytojournal_262_2024\/ref-40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-41","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.25259\/Cytojournal_262_2024\/ref-42","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1111\/jcmm.14511","article-title":"Molecular mechanisms of ferroptosis and its role in cancer therapy","volume":"23","author":"Xu","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.25259\/Cytojournal_262_2024\/ref-43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","article-title":"Converting cold into hot tumors by combining immunotherapies","volume":"170","author":"Haanen","year":"2017","journal-title":"Cell"},{"key":"10.25259\/Cytojournal_262_2024\/ref-44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: Molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res"},{"key":"10.25259\/Cytojournal_262_2024\/ref-45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","article-title":"Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells","volume":"15","author":"Yang","year":"2008","journal-title":"Chem Biol"},{"key":"10.25259\/Cytojournal_262_2024\/ref-46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2020.02.015","article-title":"Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs","volume":"483","author":"Su","year":"2020","journal-title":"Cancer Lett"},{"key":"10.25259\/Cytojournal_262_2024\/ref-47","doi-asserted-by":"publisher","first-page":"e0120877","DOI":"10.1371\/journal.pone.0120877","article-title":"A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting","volume":"10","author":"Fishman","year":"2015","journal-title":"PLoS One"},{"key":"10.25259\/Cytojournal_262_2024\/ref-48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","article-title":"Ferroptosis: A novel anti-tumor action for cisplatin","volume":"50","author":"Guo","year":"2018","journal-title":"Cancer Res Treat"}],"container-title":["Cytojournal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cytojournal.com\/combine-immune-checkpoint-indoleamine-23-dioxygenase-1-knockdown-with-ferroptosis-inducer-erastin-rsl3-accelerates-colorectal-cancer-cell-ferroptosis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cytojournal.com\/combine-immune-checkpoint-indoleamine-23-dioxygenase-1-knockdown-with-ferroptosis-inducer-erastin-rsl3-accelerates-colorectal-cancer-cell-ferroptosis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:25:28Z","timestamp":1780143928000},"score":1,"resource":{"primary":{"URL":"https:\/\/cytojournal.com\/combine-immune-checkpoint-indoleamine-23-dioxygenase-1-knockdown-with-ferroptosis-inducer-erastin-rsl3-accelerates-colorectal-cancer-cell-ferroptosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":48,"alternative-id":["10.25259\/Cytojournal_262_2024"],"URL":"https:\/\/doi.org\/10.25259\/cytojournal_262_2024","relation":{},"ISSN":["1742-6413","0974-5963"],"issn-type":[{"value":"1742-6413","type":"electronic"},{"value":"0974-5963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"32"}}